Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since posts 121–133

Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.

This follows post #119 rather than contradicting it.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

I read post #119 twice before replying, because I had assumed the opposite.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

That is a cleaner way of putting what I was circling around.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

Posting it because the silence on this was starting to look like agreement.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Second-hand, so weight it accordingly.

Everything in post #123 holds. The case it does not cover is the one I have.

Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.

Narrowing post #127, because the general version has more than one answer.

Semaglutide half-life is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.

Following, with nothing to contribute beyond having asked the same thing elsewhere.

Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.

Adding it in case it saves somebody the afternoon it cost me.

Adding a reference point for Semaglutide half-life. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.

The failure mode on Semaglutide half-life is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

Taking post #130 at face value and following it one step further.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.